World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
48735
World Ranking
11524
National Ranking
465

Natasha B. Leighl publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Natasha B. Leighl sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 799 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Natasha B. Leighl D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Natasha B. Leighl sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Natasha B. Leighl is affiliated with the Princess Margaret Cancer Centre in Canada and has made significant contributions to the field of medicine, specifically within pulmonary and respiratory medicine, oncology, and cancer research.

Their research focuses mainly on lung cancer treatments and mutations, lung cancer diagnosis and treatment, cancer genomics and diagnostics, lung cancer research studies, and cancer immunotherapy and biomarkers. Additional interests include colorectal cancer treatments and studies as well as gastric cancer management and outcomes.

Natasha B. Leighl has published extensively, with a notable presence in prominent medical journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Lung Cancer
  • Current Oncology

Their collaborative work involves a group of frequent co-authors, demonstrating long-term research partnerships. These include:

  • Frances A. Shepherd
  • Adrian G. Sacher
  • Geoffrey Liu
  • Penelope A. Bradbury
  • Ming-Sound Tsao

Significant recent papers authored by Natasha B. Leighl or co-authored in the field are as follows:

  • Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study, 2021, Journal of Clinical Oncology
  • Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer, 2021, Journal of Thoracic Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, 2020, Journal of Clinical Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, 2021, Journal of Clinical Oncology
  • Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153, 2020, Journal of Clinical Oncology

Leighl's body of work contributes to the understanding and treatment protocols of advanced lung cancer, including targeted therapies and immunotherapy options. Their research is grounded in clinical oncology with a strong focus on improving diagnostic and therapeutic strategies.

Overall, Natasha B. Leighl's contributions span multiple subfields including molecular biology and radiology, nuclear medicine, and imaging, reinforcing a multidisciplinary approach to cancer research and treatment.

Best Publications

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Monika Krzyzanowska;Breffni Hannon;Breffni Hannon

  • Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

    Martin Reck;Joachim von Pawel;Petr Zatloukal;Rodryg Ramlau

  • Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

    Thomas J. Smith;Kari Bohlke;Gary H. Lyman;Kenneth R. Carson

  • Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

    M. Reck;J Von Pawel;P. Zatloukal;R. Ramlau

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

    James D McKay;Rayjean J Hung;Younghun Han;Xuchen Zong

  • Sensitive tumour detection and classification using plasma cell-free DNA methylomes

    Shu Yi Shen;Rajat Singhania;Gordon Fehringer;Ankur Chakravarthy

  • Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis

    Rebecca G. Hagerty;Phyllis N. Butow;Peter M. Ellis;Elizabeth A. Lobb

  • CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Thanyanan Reungwetwattana;Kazuhiko Nakagawa;Byoung Chul Cho;Manuel Cobo

  • Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp

  • Cancer patient preferences for communication of prognosis in the metastatic setting.

    Rebecca G. Hagerty;Phyllis N. Butow;Peter A. Ellis;Elizabeth A. Lobb

  • Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

    Natasha B. Leighl;Ray D. Page;Victoria M. Raymond;Davey B. Daniel

  • Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature

    Giannicola D'Addario;Melania Pintilie;Natasha B. Leighl;Ronald Feld

  • Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

    Massimo Di Maio;Ciro Gallo;Natasha B. Leighl;Maria Carmela Piccirillo

  • Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study

    Keunchil Park;Eric B Haura;Natasha B Leighl;Paul L R Mitchell

  • Perceptions of palliative care among patients with advanced cancer and their caregivers

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Natasha Leighl

  • Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

    Christian Rolfo;Philip Mack;Giorgio V. Scagliotti;Charu Aggarwal

  • Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

    Nasser H. Hanna;Bryan J. Schneider;Sarah Temin;Sherman Baker

Frequent Co-Authors

Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Geoffrey Liu
Geoffrey Liu Princess Margaret Cancer Centre
Ming-Sound Tsao
Ming-Sound Tsao Princess Margaret Cancer Centre
Wei Xu
Wei Xu Shenzhen University
Suzanne Kamel-Reid
Suzanne Kamel-Reid University Health Network
Andrea Bezjak
Andrea Bezjak Princess Margaret Cancer Centre
Lesley Seymour
Lesley Seymour Queen's University
Melania Pintilie
Melania Pintilie Princess Margaret Cancer Centre
Jeffrey S. Hoch
Jeffrey S. Hoch University of California, Davis
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in advancing your medical career or exploring alternative paths? The field of healthcare offers a variety of online degrees tailored for different interests and schedules. For those looking to enter management and leadership roles in hospitals or clinics, a master's in healthcare administration online provides training in organizational leadership, policy, and operations.

Nurses aiming to reach the highest levels of clinical practice can consider the most affordable online dnp programs. These programs focus on advancing clinical expertise and leadership skills in nursing practice. Pharmacists seeking a flexible and accelerated track may benefit from the 3 year online pharmd, which enables working professionals to earn their doctorate at an expedited pace.

For those interested in the digital side of healthcare, accredited him programs offer a pathway into health information management, blending technology, administration, and healthcare knowledge. Exploring these options can expand your career opportunities while offering the flexibility of online study.

Best Scientists Citing Natasha B. Leighl

Trending Scientists

Recently Published Articles